Literature DB >> 22173137

Clinical presentation of invasive pneumococcal disease in Spain in the era of heptavalent conjugate vaccine.

Maria F de Sevilla1, Juan-José García-García, Cristina Esteva, Fernando Moraga, Sergi Hernández, Laura Selva, Francisco Coll, Pilar Ciruela, Ana Maria Planes, Gemma Codina, Luis Salleras, Iolanda Jordan, Angela Domínguez, Carmen Muñoz-Almagro.   

Abstract

BACKGROUND: The aim of this study was to analyze the rate of incidence, clinical presentation, serotype, and clonal distribution of invasive pneumococcal disease (IPD) in the era of heptavalent pneumococcal conjugate vaccine (PCV7) in Barcelona, Spain.
METHODS: This was a prospective study comprising all children <5 years with IPD who were managed in 2 tertiary-care, pediatric hospitals between January 2007 and December 2009. IPD was defined as the presence of clinical findings of infection together with isolation or detection of DNA of Streptococcus pneumoniae in a sterile fluid sample.
RESULTS: In this study, 319 patients (53.3% male), mean age 29.6 months, were included. Comparing rates in 2007 and 2009 (76.2 and 109.9 episodes/100,000 population, respectively), an increase of 44% (95% confidence interval, 10%-89%) was observed. The main clinical presentation was pneumonia (254 episodes, 79.6%), followed by meningitis (29, 9.1%), and bacteremia (25, 7.8%).The diagnosis was made by positive culture in 123 (38.6%) patients and in 196 (61.4%) by real-time polymerase chain reaction. Serotype study was performed in 300 episodes, and 273 (91%) were non-PCV7 serotypes. The most frequent serotypes were 1 (20.7%), 19A (15.7%), and 3 (12.3%). A minimal inhibitory concentration ≥0.12 μg/mL to penicillin was detected in 34.4% of isolates. Sequence type 306 expressing serotype 1 was the most frequent clonal type detected (20.3% of studied strains).
CONCLUSIONS: IPD continues to increase in Barcelona, and the rate is higher than previously reported as a result of low sensitivity of bacterial culture. Non-PCV7 serotypes were responsible for 91% of episodes and pneumonia was the main clinical presentation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22173137     DOI: 10.1097/INF.0b013e318241d09e

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  12 in total

1.  Epidemiologic and clinical implications of second-generation pneumococcal conjugate vaccines.

Authors:  Carmen Muñoz-Almagro; Adoracion Navarro-Torne; Roman Pallares
Journal:  Curr Infect Dis Rep       Date:  2013-04       Impact factor: 3.725

2.  Incidence of pneumococcal infections among children under 15 years in southern Catalonia throughout the heptavalent conjugate vaccine era, 2002-2009.

Authors:  A Vila-Corcoles; O Ochoa-Gondar; A Guzman-Avalos; F Gomez-Bertomeu; E Figuerola-Massana; X Raga-Luria; C de Diego-Cabanes; A Gutierrez-Perez; A Vila-Rovira; M Rodriguez-Fernandez
Journal:  Infection       Date:  2012-09-30       Impact factor: 3.553

3.  Invasive Pneumococcal Disease and Influenza Activity in a Pediatric Population: Impact of PCV13 Vaccination in Pandemic and Nonpandemic Influenza Periods.

Authors:  Sergi Hernández; Carmen Muñoz-Almagro; Pilar Ciruela; Núria Soldevila; Conchita Izquierdo; Maria Gemma Codina; Alvaro Díaz; Fernando Moraga-Llop; Juan José García-García; Ángela Domínguez
Journal:  J Clin Microbiol       Date:  2019-07-26       Impact factor: 5.948

4.  Changing trends in serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae causing invasive diseases in Central Thailand, 2009-2012.

Authors:  Wanatpreeya Phongsamart; Somporn Srifeungfung; Tanittha Chatsuwan; Pongpun Nunthapisud; Vipa Treerauthaweeraphong; Pimpha Rungnobhakhun; Sirintip Sricharoenchai; Kulkanya Chokephaibulkit
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  Expansion of serotype coverage in the universal pediatric vaccination calendar: short-term effects on age- and serotype-dependent incidence of invasive pneumococcal clinical presentations in Madrid, Spain.

Authors:  Juan Picazo; Jesus Ruiz-Contreras; Juan Casado-Flores; Sagrario Negreira; Maria-Jesus García-de-Miguel; Teresa Hernández-Sampelayo; Enrique Otheo; Cristina Méndez
Journal:  Clin Vaccine Immunol       Date:  2013-08-07

Review 6.  Current concepts in host-microbe interaction leading to pneumococcal pneumonia.

Authors:  Joshua Vernatter; Liise-anne Pirofski
Journal:  Curr Opin Infect Dis       Date:  2013-06       Impact factor: 4.915

Review 7.  Intranasal Vaccine Delivery Technology for Respiratory Tract Disease Application with a Special Emphasis on Pneumococcal Disease.

Authors:  William Walkowski; Justin Bassett; Manmeet Bhalla; Blaine A Pfeifer; Elsa N Bou Ghanem
Journal:  Vaccines (Basel)       Date:  2021-06-02

8.  Streptococcus pneumoniae biofilm formation is strain dependent, multifactorial, and associated with reduced invasiveness and immunoreactivity during colonization.

Authors:  Krystle Blanchette-Cain; Cecilia A Hinojosa; Ramya Akula Suresh Babu; Anel Lizcano; Norberto Gonzalez-Juarbe; Carmen Munoz-Almagro; Carlos J Sanchez; Molly A Bergman; Carlos J Orihuela
Journal:  MBio       Date:  2013-10-15       Impact factor: 7.867

9.  Recurrent invasive pneumococcal disease in children: underlying clinical conditions, and immunological and microbiological characteristics.

Authors:  Laia Alsina; Maria G Basteiro; Hector D de Paz; Melania Iñigo; Mariona F de Sevilla; Miriam Triviño; Manel Juan; Carmen Muñoz-Almagro
Journal:  PLoS One       Date:  2015-03-04       Impact factor: 3.240

10.  Incidence of pediatric invasive pneumococcal disease in the Island of Majorca (2008-2010), an area with non-universal vaccination, and estimations of serotype & children population coverage by available conjugate vaccines.

Authors:  Juan Picazo; Joaquin Dueñas; Antonio Ramirez; Andres-Ricardo Perez; Emma Padilla; Susana Herrero; Carmen Gallegos; Esther Culebras; Cesar Balseiro; Cristina Mendez
Journal:  BMC Infect Dis       Date:  2013-10-29       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.